[1. UNAIDS. AIDS epidemic update: December 2009.]Search in Google Scholar
[2. Rojanapithayakorn W. The 100% condom use programme in Asia. Reprod Health Matters. 2006; 14: 41-52.10.1016/S0968-8080(06)28270-3]Open DOISearch in Google Scholar
[3. Punyacharoensin N, Viwatwongkasem C. Trends in three decades of HIV/AIDS epidemic in Thailand by nonparametric backcalculation method. AIDS. 2009; 23:1143-52.10.1097/QAD.0b013e32832baa1c]Search in Google Scholar
[4. Johnston MI, Fauci AS. An HIV vaccine-challenges and prospects. N Engl J Med. 2008; 359:888-90.10.1056/NEJMp0806162]Search in Google Scholar
[5. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science. 2008; 321:530-2.10.1126/science.1161000]Search in Google Scholar
[6. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008; 455:613-9.10.1038/nature07352]Search in Google Scholar
[7. Berkley SF, Koff WC. Scientific and policy challenges to development of an AIDS vaccine. Lancet. 2007; 370: 94-101.10.1016/S0140-6736(07)61054-X]Search in Google Scholar
[8. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol. 2006; 7:19-23.10.1038/ni129616357854]Search in Google Scholar
[9. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005; 191:654-65.10.1086/42840415688278]Search in Google Scholar
[10. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194:1661-71.10.1086/50874817109337]Search in Google Scholar
[11. Walker BD, Burton DR. Toward an AIDS vaccine. Science. 2008; 320:760-4.10.1126/science.115262218467582]Search in Google Scholar
[12. Moore JP, Burton DR. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med. 2004; 10:769-71.10.1038/nm0804-76915286768]Search in Google Scholar
[13. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know. Nat Med. 2004; 10:806-10.10.1038/nm0804-80615286782]Search in Google Scholar
[14. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD81 cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68, 6103-10.10.1128/jvi.68.9.6103-6110.1994]Search in Google Scholar
[15. Haynes BF, Shattock RJ. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol. 2008; 122:3-9.10.1016/j.jaci.2008.03.036301457318468671]Search in Google Scholar
[16. Gupta SB, Jacobson LP, Margolick JB, Rinaldo CR, Phair JP, Jamieson BD, et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis. 2007; 4:546-50.10.1086/51090917230414]Search in Google Scholar
[17. Mattapallil JJ, Douek DC, Buckler-White A, Montefiori D, Letvin NL, Nabel GJ, et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med. 2006; 203: 1533-41.10.1084/jem.20060657211831416735692]Search in Google Scholar
[18. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol. 2006; 80:5875-85.10.1128/JVI.00171-06147261216731926]Search in Google Scholar
[19. Korber BT, Letvin NL, Haynes BF. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol. 2009; 83:8300-14. \10.1128/JVI.00114-09273816019439471]Open DOISearch in Google Scholar
[20. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008; 14:617-21.10.1038/nm.f.1759369785318535579]Search in Google Scholar
[21. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS. 1997; 11 (Suppl A): S127-37.]Search in Google Scholar
[22. Fast PE. Recent trends in clinical trials of vaccines to prevent HIV/AIDS. Curr Opin HIV AIDS. 2006; 1: 267-71.10.1097/01.COH.0000232340.77790.7a19372820]Search in Google Scholar
[23. Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology. 2008; 381:106-15.10.1016/j.virol.2008.08.019478277618793787]Search in Google Scholar
[24. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Human Vaccines. 2009; 5:1-5.10.4161/hv.969319786840]Search in Google Scholar
[25. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008; 46:1769-81.10.1086/58799318433307]Search in Google Scholar
[26. Spearman P: HIV Vaccine Development. Lessons from the Past and Promise for the Future. Curr HIV Res. 2003; 1:101-20.10.2174/157016203335209315043215]Search in Google Scholar
[27. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007; 25:4085-92.10.1016/j.vaccine.2007.02.05017391815]Search in Google Scholar
[28. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008; 205:63-77.10.1084/jem.20071331223437118195071]Search in Google Scholar
[29. Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr. 2007; 45:20-7.10.1097/QAI.0b013e3180377b5b17310936]Search in Google Scholar
[30. Vaccari M, Mattapallil J, Song K, Tsai WP, Hryniewicz A, Venzon D, et al. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol. 2008; 82: 9629-38.10.1128/JVI.00893-08254695718667509]Search in Google Scholar
[31. Engram JC, Dunham RM, Makedonas G, Vanderford TH, Sumpter B, Klatt NR, et al. Vaccine-induced, Simian Immunodeficiency Virus-specific CD8+ T cells reduce virus replication but do not protect from Simian Immunodeficiency Virus disease progression. J Immunol. 2009; 183:706-17.10.4049/jimmunol.080374619542473]Search in Google Scholar
[32. Ramsburg E, Rose NF, Marx PA, Mefford M, Nixon DF, Moretto WJ, et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol. 2004; 78:3930-40.10.1128/JVI.78.8.3930-3940.2004]Open DOISearch in Google Scholar
[33. Amara RR, Villinger F, Altman JD, Lydy SL, O’Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001; 292:69-74.10.1126/science.292.5514.69]Search in Google Scholar
[34. WHO/UNAIDS/IAVI International Expert Group. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on ‘Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines’, 31 January-2 February 2006, IAVI, New York, USA. AIDS. 2007; 21:539-46.10.1097/QAD.0b013e328011a0c9]Search in Google Scholar
[35. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, testof- concept trial. Lancet. 2008; 372:1881-93.10.1016/S0140-6736(08)61591-3]Search in Google Scholar
[36. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a casecohort analysis. Lancet. 2008; 372:1894-905.10.1016/S0140-6736(08)61592-5]Search in Google Scholar
[37. Gray G. Results from the Phambili (HVTN 503) study: a multicenter phase IIB test-of-concept study of the MRKad5 HIV-1 gag/pol/nef vaccine in South Africa. Presented at AIDS Vaccine 2008, Cape Town, South Africa, October 13-16, 2008.]Search in Google Scholar
[38. Excler JL, Rida W, Priddy F, Fast P, Koff W. A strategy for accelerating the development of preventive AIDS vaccines. AIDS. 2007; 21:2259-63.10.1097/QAD.0b013e3282eee70c18090273]Search in Google Scholar
[39. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine ‘prime-boost’ phase III trial: foundations and initial lessons learned from Thailand. AIDS. 2006; 20: 1471-9.10.1097/01.aids.0000237362.26370.f816847401]Search in Google Scholar
[40. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med. 2009; 361:2209-20.10.1056/NEJMoa090849219843557]Search in Google Scholar
[41. Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Rev Vaccines. 2008; 7:311-7.10.1586/14760584.7.3.31118393601]Open DOISearch in Google Scholar
[42. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr. 2007; 46:48-55.10.1097/QAI.0b013e3181354bd717909315]Search in Google Scholar
[43. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, et al. Antibodydependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/ AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005; 23:2522-9.10.1016/j.vaccine.2004.10.02815752839]Open DOISearch in Google Scholar
[44. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194:1661-71.10.1086/50874817109337]Search in Google Scholar
[45. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 2004; 303:316.10.1126/science.109462014726576]Search in Google Scholar
[46. Phogat S, Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des. 2007; 13:213-27.10.2174/13816120777931363217269929]Open DOISearch in Google Scholar
[47. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008; 72:54-84.10.1128/MMBR.00006-08]Open DOISearch in Google Scholar
[48. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature.2007; 446:1038-45.10.1038/nature0581817460665]Search in Google Scholar
[49. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009; 83: 7337-48.10.1128/JVI.00110-09270477819439467]Search in Google Scholar
[50. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009; 326:285-9.10.1126/science.1178746333527019729618]Search in Google Scholar
[51. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009; 15:901-6.10.1038/nm.1967272317719448633]Open DOISearch in Google Scholar
[52. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther. 2008; 19:663-9.10.1089/hum.2008.033294063418549307]Open DOISearch in Google Scholar
[53. Sharpe S, Polyanskaya N, Dennis M, Sutter G, Hanke T, Erfle V, et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol. 2001; 82:2215-23.10.1099/0022-1317-82-9-221511514732]Search in Google Scholar
[54. Koff WC, Parks CL, Berkhout B, Ackland J, Noble S, Gust ID. Replicating viral vectors as HIV vaccines summary report from IAVI sponsored satellite symposium, International AIDS Society Conference, July 22, 2007. Biologicals. 2008; 36:277-86.10.1016/j.biologicals.2008.04.00418555698]Search in Google Scholar
[55. Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG. HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. Curr HIV Res. 2007; 5:97-107.10.2174/15701620777931626017266561]Search in Google Scholar
[56. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol. 2006; 6:417-23.10.1038/nri184016622477]Open DOISearch in Google Scholar
[57. D’Souza MP, Altfeld M. Measuring HIV specific T cell immunity: how valid are current assays? J Infect Dis. 2008; 197:337-9.10.1086/525288]Search in Google Scholar
[58. Chuenchitra T, Sukwit S, Gaywee J, Viputtikul K, Eamsila C, Tabprasit S, et al. The development of HIV research laboratories in the Royal Thai Army Medical Department. J Med Assoc Thai. 2005; 88 (Suppl 3):S317-24.]Search in Google Scholar
[59. Fauce SR, Yang OO, Effros RB. Autologous CD4/CD8 co-culture assay: A physiologically-relevant composite measure of CD8(+) T lymphocyte function in HIVinfected persons. J Immunol Methods. 2007; 327: 75-81.10.1016/j.jim.2007.07.017215192817716683]Search in Google Scholar
[60. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker BM, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol. 2009; 83:3138-49.10.1128/JVI.02073-08265555819158248]Open DOISearch in Google Scholar
[61. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, et al. Correlation of vaccine-elicited systemic and mucosal non-neutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol. 2009; 83: 791-801. 10.1128/JVI.01672-08261236518971271]Search in Google Scholar
[62. Excler JL. AIDS vaccine efficacy trials: expand capacity and prioritize. ‘Throughout Africa, Asia and Latin America state-of-the-art clinics and laboratories.exist where, 4 years ago, there were none’. Expert Rev Vaccines. 2006; 5:167-70.10.1586/14760584.5.2.16716608417]Search in Google Scholar
[63. Excler JL, Pitisuttithum P, Rerks-Ngarm S, Shao Y, Zhang L, Tamashiro H, Osmanov S; WHO-UNAIDS Regional Consultation. Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian J Trop Med Public Health. 2008; 39: 766-84.]Search in Google Scholar
[64. Ananworanich J, Phanuphak N, de Souza M, Paris R, Arroyo M, Trichavaroj R, et al. Incidence and characterization of acute HIV-1 infection in a highrisk Thai population. J Acquir Immune Defic Syndr. 2008; 49:151-5.10.1097/QAI.0b013e318183a96d18769355]Search in Google Scholar
[65. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008; 5:e157; discussion e157.10.1371/journal.pmed.0050157249456218684007]Open DOISearch in Google Scholar
[66. Moore JP, Veazey RA, Barouch D. Can Vaccines and Microbicides be Co-developed? Presented at AIDS Vaccine 2008, Cape Town, South Africa, October 13-16, 2008. [Abstract RT01-01].]Search in Google Scholar
[67. Plotkin SA. Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc. 2009; 12:2.10.1186/1758-2652-12-2]Search in Google Scholar